Cormorant Asset Management, LP's Net Worth

$1.28 Billion

Who is Cormorant Asset Management, LP?

Cormorant Asset Management, LP has an estimated net worth of $1.28 Billion. This is based on reported shares across multiple companies, which include Corbus Pharmaceuticals Holdings, Inc., Turning Point Therapeutics, Inc., Vigil Neuroscience, Inc., Prometheus Biosciences, Inc., Ambrx Biopharma, Inc., Design Therapeutics, Inc., Kezar Life Sciences, Inc., Icosavax, Inc., Atea Pharmaceuticals, Inc., Kiniksa Pharmaceuticals, Ltd., Ventyx Biosciences, Inc., Axonics Modulation Technologies, Inc., Tyra Biosciences, Inc., Erasca, Inc., Monte Rosa Therapeutics, Inc., Verve Therapeutics, Inc., Aerovate Therapeutics, Inc., Avidity Biosciences, Inc., Apellis Pharmaceuticals, Inc., Immuneering Corp, Pyxis Oncology, Inc., Elevation Oncology, Inc., PROTEOSTASIS THERAPEUTICS, INC., BioAtla, Inc., Ambrx Biopharma Inc., Biomea Fusion, Inc., Rain Therapeutics Inc., Akouos, Inc., Cellectar Biosciences, Inc., Olema Pharmaceuticals, Inc., Clearside Biomedical, Inc., GreenLight Biosciences Holdings, PBC, CONSTELLATION PHARMACEUTICALS INC, MoonLake Immunotherapeutics, and EyePoint Pharmaceuticals, Inc..

SEC CIK

Cormorant Asset Management, LP's CIK is 0001583977

Past Insider Trading and Trends

2023 was Cormorant Asset Management, LP's most active year for acquiring shares with 37 total transactions. Cormorant Asset Management, LP's most active month to acquire stocks was the month of November. 2021 was Cormorant Asset Management, LP's most active year for disposing of shares, totalling 15 transactions. Cormorant Asset Management, LP's most active month to dispose stocks was the month of October. 2023 saw Cormorant Asset Management, LP paying a total of $207,445,307.04 for 15,599,466 shares, this is the most they've acquired in one year. In 2023 Cormorant Asset Management, LP cashed out on 9,188,659 shares for a total of $0.00, their largest year based on trade value.